All In Biotech

Drug Trial Radar · NCT00853606

Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction

An Open-Label, Long-Term Evaluation of the Safety and Efficacy of Avanafil in Men With Erectile Dysfunction

Last checked: Nov 20, 2026Latest source record: Aug 17, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

712

Actual

Start

Mar 2009

Primary completion

Apr 2010

Study completion Apr 2010

Sponsor

Lead sponsor
VIVUS LLCIndustry
Sponsor type
Industry
First posted
Mar 2, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label study is being conducted to evaluate the long-term safety, tolerability, and efficacy of avanafil in men with mild to severe erectile dysfunction. Approximately 400 subjects will be enrolled and treated with avanafil for up to 52 weeks.

Conditions

  • Erectile Dysfunction

Interventions

  • avanafilDrug

    All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse.Time frame: Baseline, 52 weeks
  2. Change in Percentage of Sexual Attempts in Which Subjects Were Able to Insert the Penis Into the Partner's VaginaTime frame: Baseline, 52 weeks
  3. Change in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) ScoreTime frame: Baseline, End of Treatment

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Homewood, Alabama

  • Research Site

    Tucson, Arizona

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Clearwater, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Coral Gables, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Jupiter, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Ponte Vedra, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Sandy Springs, Georgia

  • Research Site

    Wichita, Kansas

  • Research Site

    Madisonville, Kentucky

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Kansas City, Missouri

  • Research Site

    Lawrenceville, New Jersey

  • Research Site

    Albany, New York

  • Research Site

    New York, New York

  • Research Site

    Cary, North Carolina

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Harrisburg, North Carolina

  • Research Site

    Hickory, North Carolina

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Salisbury, North Carolina

  • Research Site

    Wilmington, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Bala-Cynwyd, Pennsylvania

  • Research Site

    Lancaster, Pennsylvania

  • Research Site

    El Paso, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Spring, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.